EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Interindividual variability in CYP3A ‐mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia

Jonghwa Lee iD, Jessica L Beers iD, Isabel Cheng, Vivian Truong, Zachary Brown iD, Benyam Muluneh iD, Catherine C Coombs iD, Klarissa D Jackson iD

Clinical and Translational Science · 2024-12 · 17 (12)

DOI: 10.1111/cts.70106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 14.12.2024. Verfasst von Jonghwa Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Chapel Hill, Nort…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Cytochrome P-450 CYP3A. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax is a first‐in‐class orally administered B‐cell lymphoma‐2 inhibitor used to treat chronic lymphocytic leukemia (CLL). Venetoclax is primarily metabolized in the liver by cytochrome P450 (CYP) 3A4 to its major metabolite M27, via M5, and M2, M3, and M4 via oxidation. Although venetoclax is a breakthrough in CLL treatment, managing drug safety and toxicity remains a clinical challenge. The objectives of this study were to investigate how individual CYP3A activity and protein expression affect hepatic venetoclax metabolism in vitro and examine whether plasma 4β‐hydroxycholesterol (4β‐HC)/cholesterol ratio can predict venetoclax metabolism in vitro and in vivo. In human liver microsomes ( n = 20) and primary human hepatocytes ( n = 15), venetoclax metabolite formation varied widely between donors and significantly correlated with CYP3A activity (midazolam 1′‐hydroxylation) and CYP3A4 protein expression. Venetoclax metabolite formation positively correlated with 4β‐HC/cholesterol ratio in plasma samples from the matched non‐infant donors ( n = 14, ages 3–63 years). In an observational pilot study of real‐world patients with CLL ( n = 12, ages 56–84 years) treated with venetoclax, the plasma M3/venetoclax metabolic ratio negatively correlated with plasma 4β‐HC/cholesterol ratio and positively correlated with patient age. Plasma 4β‐HC/cholesterol ratio negatively correlated with patient age. Differences between the in vitro data, which showed a positive association between venetoclax metabolism, hepatic CYP3A markers, and plasma 4β‐HC/cholesterol ratio, and the in vivo findings in patients with CLL could be due to age or other factors regulating plasma 4β‐HC/cholesterol and/or venetoclax disposition. Future studies with larger sample sizes are needed to investigate age‐related changes in venetoclax metabolism and plasma 4β‐HC/cholesterol ratio.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellBridged Bicyclo Compounds, HeterocyclicSulfonamidesCytochrome P-450 CYP3AMicrosomes, LiverHumansMiddle AgedAgedMaleFemaleHepatocytesAged, 80 and overAntineoplastic AgentsAdultCholesterolHydroxycholesterols

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesCytochrome P-450 CYP3AAntineoplastic AgentsCYP3A protein, humanCholesterolHydroxycholesterols

Autor:innen und Institutionen

  • Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill Eshelman School of Pharmacy, Chapel Hill, North Carolina, USA.
  • Division of Hematology/Oncology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.

ORCID-Profile: Jonghwa Lee, Jessica L Beers, Zachary Brown, Benyam Muluneh, Catherine C Coombs, Klarissa D Jackson

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Lee, J., Beers, J. L., Cheng, I., Truong, V., Brown, Z., Muluneh, B., Coombs, C. C., & Jackson, K. D. (2024). Interindividual variability in CYP3A ‐mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia. Clinical and Translational Science, 17(12). https://doi.org/10.1111/cts.70106

Vancouver

Lee J, Beers JL, Cheng I, Truong V, Brown Z, Muluneh B, et al. Interindividual variability in CYP3A ‐mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia. Clinical and Translational Science. 2024;17(12). doi:10.1111/cts.70106

BibTeX
@article{Lee2024,
  author = {Lee, Jonghwa and Beers, Jessica L and Cheng, Isabel and Truong, Vivian and Brown, Zachary and Muluneh, Benyam and Coombs, Catherine C and Jackson, Klarissa D},
  title = {Interindividual variability in CYP3A ‐mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia},
  journal = {Clinical and Translational Science},
  year = {2024},
  volume = {17},
  number = {12},
  doi = {10.1111/cts.70106}
}
Kostenlos starten →